Our TAP Centres and Nurses

The Trials Acceleration Programme (TAP)

In January 2020, Cure Leukaemia began a 3-year, £3,000,000 commitment to funding the national Trials Acceleration Programme (TAP). This integrated and collaborative network consists of 12 specialist research nurses in 12 of the UK's biggest cities and a facilitatory Hub based at the Centre for Clinical Haematology in Birmingham. This network enables the accelerated setup, recruitment to and delivery of pioneering blood cancer clinical trials connecting patients from a catchment area of over 20 million people with potentially life-saving treatments not currently available through standard care.

Here we introduce some of the clinicians and nurses at these sites to emphasise the importance of funds raised for Cure Leukaemia in sustaining this vital network.

 


Birmingham - Make a donation to support this centre HERE


Nottingham - Make a donation to support this centre HERE


Sheffield - Make a donation to support this centre HERE


Oxford - Make a donation to support this centre HERE


Cardiff - Make a donation to support this centre HERE


Southampton - Make a donation to support this centre HERE


Belfast - Make a donation to support this centre HERE


Glasgow - Make a donation to support this centre HERE


Manchester - Make a donation to support this centre HERE


Leeds - Make a donation to support this centre HERE


London - Make a donation to support these centres HERE

To make a donation specific to any of these centres please click HERE and donate on the JustGiving page relevant to each centre, thank you.

What we do

The Trials Acceleration Programme (TAP)

How funds raised for Cure Leukaemia help save lives

Cure Leukamia Pre footer image
"Cure Leukaemia’s funding of the UK Trials Acceleration Programme (TAP) is a game-changer and increases the access for blood cancer patients to potentially transformative new therapies."

Sir John Bell
"Cure Leukaemia’s funding of the UK Trials Acceleration Programme (TAP) is a game-changer and increases the access for blood cancer patients to potentially transformative new therapies."

Sir John Bell